Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16925966 | 1.00 | VHL (0.52) | VHLOPRM1OPRD1CALCRL | |
| SCHEMBL19381670 | 1.00 | VHL (0.52) | VHLOPRM1OPRD1CALCRL | |
| SCHEMBL16925967 | 0.96 | VHL (0.49) | VHLOPRM1OPRD1 | |
| SCHEMBL19381804 | 0.94 | VHL (0.51) | VHLOPRM1OPRD1 | |
| SCHEMBL16925995 | 0.89 | VHL (0.46) | VHLOPRM1OPRD1 | |
| SCHEMBL19381684 | 0.88 | VHL (0.48) | VHLOPRM1OPRD1CALCRL | |
| SCHEMBL16925994 | 0.87 | VHL (0.44) | VHLOPRM1OPRD1 | |
| SCHEMBL16925974 | 0.85 | VHL (0.44) | VHLOPRM1OPRD1 | |
| SCHEMBL16925968 | 0.83 | VHL (0.44) | VHLOPRM1OPRD1CALCRL | |
| SCHEMBL16925996 | 0.81 | VHL (0.47) | VHLOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739309-A1 | DANEGAPTIDE FOR USE IN TREATING SYNUCLEINOPATHIES | Cambridge Enterprise Limited (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | disclosed |
| EP-4452260-B1 | GAP JUNCTION MODULATORS AND THEIR USE FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | BREYE THERAPEUTICS APS (DK) | 2026-01-28 | — | — | EP | disclosed |
| EP-4677087-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | Glaukos Corporation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | INFLAMMX THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250221936-A1 | ENGINEERED HEMICHANNELS, ENGINEERED VESICLES, AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250136987-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250127851-A1 | CYTOKINE MODULATION | INFLAMMX THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20250018002-A1 | Gap Junction Modulators and Their Use for the Treatment of Age-Related Macular Degeneration | BREYE THERAPEUTICS APS (DK) | 2025-01-16 | — | — | US | disclosed |
| EP-4491184-A2 | CHANNEL MODULATORS | Auckland Uniservices Limited (NZ) | 2025-01-15 | — | — | EP | disclosed |
| EP-3082768-B1 | LIPOSOMAL MITIGATION OF DRUG-INDUCED INHIBITION OF THE CARDIAC IKR CHANNEL | SIGNPATH PHARMA INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220288163-A1 | CYTOKINE MODULATION | INFLAMMX THERAPEUTICS, INC. | 2022-09-15 | — | — | US | disclosed |
| WO-2022171525-A1 | DANEGAPTIDE FOR USE IN THE TREATMENT OR PREVENTION OF A KIDNEY DISEASE | CIANA THERAPEUTICS APS (DK) | 2022-08-18 | — | — | WO | disclosed |
| US-11401516-B2 | Channel modulators | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-08-02 | — | — | US | disclosed |
| US-11344603-B2 | Cytokine modulation | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-05-31 | — | — | US | disclosed |
| CN-114524885-A | Auricularia auricula polysaccharide and application thereof | 吉林农业大学 | 2022-05-24 | — | — | CN | disclosed |
| US-11324799-B2 | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease | ZEALAND PHARMA A/S (DK) | 2022-05-10 | — | — | US | disclosed |
| EP-3958886-A1 | COMPOSITIONS AND METHODS FOR PROTECTING EPITHELIAL AND BARRIER INTEGRITY | Ocunexus Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114010788-A | Channel modulators | 奥克兰联合服务有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-114025786-A | Compositions and methods for protecting epithelial and barrier integrity | 欧耐柯萨斯医疗有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | P2RX7, NLRP3, PYCARD | VHL 2374/4885OPRM1 3404/4885OPRD1 3942/4885 |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | NLRP3, GJA1, PYCARD | VHL 1659/4885OPRM1 3099/4885OPRD1 3363/4885 |
| US-20250018002-A1 | Gap Junction Modulators and Their Use for the Treatment of Age-Related Macular Degeneration | GJA1, GJB2, VEGFA | VHL 3016/4885OPRM1 2599/4885OPRD1 2679/4885 |
| US-20250127851-A1 | CYTOKINE MODULATION | TNF, IL2, IL1B | VHL 423/4885OPRM1 1795/4885OPRD1 1860/4885 |
| US-20220288163-A1 | CYTOKINE MODULATION | TNF, IL2, IL1B | VHL 423/4885OPRM1 1795/4885OPRD1 1860/4885 |
| US-11401516-B2 | Channel modulators | GJB2, GJA1, P2RX2 | VHL 809/4885OPRM1 655/4885OPRD1 1119/4885 |
| US-11344603-B2 | Cytokine modulation | TNF, IL2, IL1B | VHL 423/4885OPRM1 1795/4885OPRD1 1860/4885 |
| US-20250136987-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | VHL 809/4885OPRM1 655/4885OPRD1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.